. 2019 Aug 13;4(2):2381468319852594. doi: 10.1177/2381468319852594

Table 3.

Health States in Thyroid Cancer

Author	Health State	Respondents	Scaling Method	Analysis N	Mean (SD); Median (Q1, Q3)
Lubitz et al⁷⁷ (2017)	Preoperation	All participants	EQ-5D	117	0.895 (0.103); 0.876 (0.82, 1)
			SF-6D	117	0.773 (0.125); 0.793 (0.66, 0.86)
			HUI-2	117	0.875 (0.133); 0.917 (0.83, 0.95)
			HUI-3	117	0.859 (0.185); 0.919 (0.79, 0.97)
	Postoperation	All participants	EQ-5D	117	0.882 (0.114, 95% CI: 0.665, 1)
			SF-6D	117	0.748 (0.117, 95% CI: 0.548, 0.919)
			HUI-2	117	0.873 (0.120, 95% CI: 0.647, 1)
			HUI-3	117	0.843 (0.167, 95% CI: 0.518, 1)
	26 weeks postoperation	All participants	EQ-5D	117	0.911 (0.107, 95% CI: 0.752, 1)
			SF-6D	117	0.798 (0.122, 95% CI: 0.609, 0.922)
			HUI-2	117	0.879 (0.111, 95% CI: 0.705, 1)
			HUI-3	117	0.863 (0.136, 95% CI: 0.596, 1)
Choi et al⁷⁸ (2013)	Thyroid cancer	All participants	VAS	32	0.10 (Median)^a
		Oncologists	VAS	12	0.11 (Median)^a
		Dermatologists	VAS	8	0.08 (Median)^a
		Psychiatrists	VAS	12	0.09 (Median)^a
Esnaola et al⁶² (2001)	Disease-free after thyroid lobectomy	All participants	TTO	15	0.99
	Disease-free after total thyroidectomy/radioiodine therapy			15	0.95
	Disease-free after thyroid surgery/permanent complication			15	0.88
	Disease-free after surgery for cervical recurrence			15	0.95
	Systemic recurrence			15	0.60
Kent et al⁷⁹ (2015)	Thyroid cancer	All participants	SF-6D	386	0.70 (95% CI: 0.69, 0.71)
Fordham et al⁷⁶ (2015)	Stable/no response	All participants	TTO	100	0.80 (0.19, 95% CI: 0.77, 0.84)
	Response to therapy				0.86 (0.15, 95% CI: 0.83, 0.89)
	Progressive disease				0.50 (0.28, 95% CI: 0.45, 0.56)
	Stable + Grade 3 diarrhea				0.42 (0.29, 95% CI: 0.36, 0.48)
	Stable + Grade 3 fatigue				0.72 (0.24, 95% CI: 0.67, 0.77)
	Stable + Grade 3 hand and foot syndrome				0.52 (0.30, 95% CI: 0.46, 0.58)
	Stable + Grades 1 or 2 alopecia				0.75 (0.21, 95% CI: 0.71, 0.79)
Borget et al⁸⁰ (2015)	At treatment assignment	THW	EQ-5D	336	0.87
	Immediately before radioiodine administration	THW		336	0.84
	2 weeks	THW		336	0.82
	4 weeks	THW		336	0.85
	6 weeks	THW		336	0.87
	3 months	THW		336	0.88
	8 months	THW		336	0.90
	At treatment assignment	rhTSH		348	0.84
	Immediately before radioiodine administration	rhTSH		348	0.85
	2 weeks	rhTSH		348	0.86
	4 weeks	rhTSH		348	0.86
	6 weeks	rhTSH		348	0.87
	3 months	rhTSH		348	0.86
	8 months	rhTSH		348	0.88
	At radioidine administration	THW		336	0.833 (0.192)
		rhTSH		348	0.849 (0.173)
		3.7 GBq radioidine activity		337	0.836 (0.184)
		1.1 GBq radioidine activity		347	0.846 (0.182)

CI, confidence interval; rhTSH, patients managed with recombinant human thyroid-stimulation hormone; THW, patients managed with thyroid hormone withdrawal; VAS, visual analogue scale.

Reported as disutility weights.